Project Grant R44HL158281
Award Date
3/4/22
Completion Date
2/28/23
Dollars Obligated
$3.5M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to develop feedback-controlled closed-loop manufacturing processes for differentiating human pluripotent stem cells into cardiomyocytes. The $590,283 award, made on February 1, 2025, will fund the University of Wisconsin-Madison's research to improve the robustness and reproducibility of this stem cell differentiation process....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,249,307 to support research aimed at understanding and overcoming the immaturity of pluripotent stem cell-derived cardiomyocytes (PSC-CMs). The project seeks to identify critical gene regulatory networks underlying the premature arrest of PSC-CM maturation, with the goal of developing transcriptome-based strategies to improve the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $815,510 to the University of Chicago to conduct research aimed at developing a genetic-based classifier to predict cancer patients' susceptibility to drug-induced cardiovascular toxicity. The research involves applying single-cell sequencing to cardiac guided differentiation cultures to study the effects of three anticancer drugs -...
This federal Project Grant award, with funding of $143,829 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as robust models for studying how intrinsic circadian regulation impacts cardiomyocyte size and function. The award also seeks to determine if mutations affecting cardiomyocyte size and function also disrupt cardiomyocyte clock...
This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a comprehensive research project to investigate the development of diverse cardiac cell types and their organization into heart structures. The $1,451,467 award, with a project period from July 1, 2024 to June 30, 2028, will be performed by the University of California, San Diego (UCSD). The research aims to identify and examine...
This $817,208 Project Grant was awarded on January 3, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research at the Broad Institute of MIT and Harvard to investigate the genetic basis and underlying mechanisms of heart failure (HF). The project will leverage high-throughput assays, including cell painting and Perturb-seq, to link genes associated with HF risk through genome-wide association...
This $580,863 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of silicon nanowire-engineered human cardiac organoids for heart repair. The key products or services to be delivered include: Optimizing the surface roughness of electrically conductive silicon nanowires (e-SiNWs) to improve their electrical interactions with human pluripotent stem cell-derived cardiomyocytes...
This $1,488,899 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the advanced development and validation of two innovative compounds, YT-002 and YT-004, targeting protein kinase C to preserve myocardial tissue and function following heart attacks. The research aims to optimize the pharmacokinetic and pharmacodynamic profiles of these compounds, conduct long-term safety and efficacy studies...